Oncology Vol 29 No 10

October 15, 2015

You may have noticed that the issue you received last month looked a little different than what you’re used to seeing from the ONCOLOGY journal!

October 15, 2015

In this interview we discuss the results of the CLEOPATRA trial, which studied the effect of adding pertuzumab to docetaxel and trastuzumab on HER2-positive metastatic breast cancer.

October 15, 2015

We will discuss the deleterious cardiovascular effects of anthracyclines and HER2-targeted agents in a case-based format, as well as specific approaches to prevention and treatment of associated cardiotoxicity.

October 15, 2015

The absence of any effective combinatorial therapy in patients progressing on bevacizumab and evidence supporting both continuation and discontinuation of bevacizumab in this setting remain important areas for additional clinical trial evaluation in order to better guide our therapeutic decision making in the clinic.

October 15, 2015

While breast-conserving surgery after neoadjuvant chemotherapy has become more accepted over time, methods of management of the axillary lymph nodes have remained matters of controversy.

October 15, 2015

It is incumbent on melanoma and radiation oncology researchers alike to further our understanding of when and how RT can help patients.

October 15, 2015

The treatment of patients with follicular lymphoma is undergoing a substantial shift due to rapid development of highly effective agents targeting lymphoma-specific biologic processes and the tumor microenvironment.

October 15, 2015

The diversity and complexity, combined with the rarity of salivary gland malignancies, lead to definite and distinct challenges in their study, and consequently in advancing treatment options for affected patients.